Was part D a giveaway to the pharmaceutical industry?

Inquiry

Volumn 44, Issue 1, 2007, Pages 15-25

  Newhouse, Joseph P ^a,c   Seiguer, Erica ^b   Frank, Richard G ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Harvard Medical School ^*

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALENDRONIC ACID; ALOSETRON; AMINOLEVULINIC ACID; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; BECAPLERMIN; BENAZEPRIL; BORTEZOMIB; CARVEDILOL; CELECOXIB; CETIRIZINE; CINACALCET; CITALOPRAM; CONJUGATED ESTROGEN; DELAVIRDINE; DONEPEZIL; DOXERCALCIFEROL; ENFUVIRTIDE; ENTACAPONE; ERLOTINIB; ESOMEPRAZOLE; ETANERCEPT; ETIRACETAM; EZETIMIBE; FELODIPINE; FEXOFENADINE; FLUINDOSTATIN; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GABAPENTIN; GEFITINIB; GENERIC DRUG; GLIMEPIRIDE; GLIPIZIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INSULIN ASPART; INSULIN LISPRO; IPRATROPIUM BROMIDE; LANSOPRAZOLE; LATANOPROST; LEVOTHYROXINE SODIUM; LINEZOLID; LISINOPRIL; LORATADINE; LOSARTAN POTASSIUM; MEMANTINE; METFORMIN; METOPROLOL SUCCINATE; MIGLITOL; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; NATEGLINIDE; NEVIRAPINE; NORADRENALIN UPTAKE INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMEPRAZOLE; PANTOPRAZOLE; PARICALCITOL; PAROXETINE; PIOGLITAZONE; PRAVASTATIN; PROSTAGLANDIN E1; PROSTAVASIN; QUINAPRIL; RABEPRAZOLE; RALOXIFENE; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; REPAGLINIDE; RESCULAR; RETINOIC ACID; RISEDRONIC ACID; RITONAVIR; ROFECOXIB; ROSIGLITAZONE; SALMETEROL XINAFOATE; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SIMVASTATIN; SPRIVA; SUMATRIPTAN SUCCINATE; TAMOXIFEN; TAMSULOSIN; TEGASEROD; TELITHROMYCIN; TOLCAPONE; TRIAMTERENE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VARDENAFIL; WARFARIN; ZAFIRLUKAST; ZILEUTON; ZOLPIDEM TARTRATE;

COMPETITION; DRUG CLASSIFICATION; DRUG COST; DRUG FORMULARY; DRUG INDUSTRY; HEALTH CARE POLICY; HEALTH SERVICE; LAW; MEDICAID; MEDICARE; PROSPECTIVE PAYMENT; REIMBURSEMENT; REVIEW;

EID: 34249948654     PISSN: 00469580     EISSN: None     Source Type: Journal    
DOI: 10.5034/inquiryjrnl_44.1.15     Document Type: Review

References (11)

1. AARP Public Policy Institute. 2004. Trends in Manufacturer Prices of Brand Name Prescription Drugs Used by Older Americans, 2000 through 2003. June. Washington, D.C.: AARP Public Policy Institute.
2. Agency for Healthcare Research and Quality (AHRQ). 2004. Puf Main Data Results. November. Rockville, Md.: AHRQ. http://www. meps.ahrq.gov/Puf/ PufDetail.asp
3. Centers for Medicare and Medicaid Services (CMS). 2005. Ensuring the Success of the New Medicare Drug Benefit. Issue Paper #24 Jan. 19.
4. DiMasi, J. A., and C. Paquette. 2004. The Economics of Follow-on Drug Research and Development: Trends in Entry Rates and the Timing of Development. Pharmacoeconomics 22(2):1-14.
5. Lu, Z. J., and W. S. Comanor. 1998. Strategic Pricing of New Pharmaceuticals. Review of Economics and Statistics 80(1):108-118.
6. Medicare Payment Advisory Commission (MedPAC). 2006. Report to the Congress: Increasing the Value of Medicare. June. Washington, D.C.: MedPAC.
7. Newhouse, J. P. 2004. How Much Should Medicare Pay for Drugs? Health Affairs 23(1):89-102.
8. Office of Technology Assessment. 1990. Recombinant Erythropoetin: Payment Options for Medicare. Washington, D.C.: Government Printing Office.
9. Pear, R. 2003. Medicare Debate Turns to Pricing of Drue Benefits. New York Times Nov. 24: A1.
10. Pear, R., and R. Toner. 2003a. As House Debate Continues, Medicare Bill Nears Vote. New York Times Nov. 22:A1.
11. _. 2003b. A Final Push in Congress. New York Times Nov. 23:A1.